498 related articles for article (PubMed ID: 29322294)
1. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
Gareau AJ; Brien C; Gebremeskel S; Liwski RS; Johnston B; Bezuhly M
Clin Exp Metastasis; 2018 Feb; 35(1-2):25-35. PubMed ID: 29322294
[TBL] [Abstract][Full Text] [Related]
2. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer.
Gebremeskel S; LeVatte T; Liwski RS; Johnston B; Bezuhly M
Int J Cancer; 2015 Jan; 136(1):234-40. PubMed ID: 24798403
[TBL] [Abstract][Full Text] [Related]
3. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
4. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
5. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
6. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
[TBL] [Abstract][Full Text] [Related]
8. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
9. Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane.
Rabani V; Montange D; Meneveau N; Davani S
Platelets; 2018 Nov; 29(7):709-715. PubMed ID: 29020490
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor to prevent restenosis: new drug for an old hypothesis?
Cayla G; Montalescot G; Collet JP
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2320-2. PubMed ID: 21084699
[No Abstract] [Full Text] [Related]
11. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Reiner MF; Akhmedov A; Stivala S; Keller S; Gaul DS; Bonetti NR; Savarese G; Glanzmann M; Zhu C; Ruf W; Yang Z; Matter CM; Lüscher TF; Camici GG; Beer JH
Cardiovasc Res; 2017 Jan; 113(1):61-69. PubMed ID: 28028070
[TBL] [Abstract][Full Text] [Related]
12. P2Y12 Receptor Modulates Sepsis-Induced Inflammation.
Liverani E; Rico MC; Tsygankov AY; Kilpatrick LE; Kunapuli SP
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):961-71. PubMed ID: 27055904
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y
Rollini F; Franchi F; Thano E; Faz G; Park Y; Kureti M; Cho JR; Been L; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2017 Jul; 10(13):1374-1375. PubMed ID: 28683943
[No Abstract] [Full Text] [Related]
15. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Cooke NM; Spillane CD; Sheils O; O'Leary J; Kenny D
BMC Cancer; 2015 Sep; 15():627. PubMed ID: 26353776
[TBL] [Abstract][Full Text] [Related]
16. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions.
Wenzel J; Zeisig R; Fichtner I
Clin Exp Metastasis; 2010; 27(1):25-34. PubMed ID: 19916050
[TBL] [Abstract][Full Text] [Related]
18. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
Schrottmaier WC; Kral JB; Badrnya S; Assinger A
Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
[TBL] [Abstract][Full Text] [Related]
19. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor inverse agonist activity at the P2Y
Khalil J; Dimofte T; Roberts T; Keith M; Amaradasa K; Hindle MS; Bancroft S; Hutchinson JL; Naseem K; Johnson T; Mundell SJ
Br J Pharmacol; 2024 Jan; 181(1):21-35. PubMed ID: 37530222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
